## CLAIMS

1. A pharmaceutical compostion comprising at least one active principe selected from (i) 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran in the form of base, (ii) 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran in the form of a pharmaceutically acceptable salt, ~~characterized in that it further~~this salt being selected from 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran hydrochloride, 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran fumarate and 2-n-butyl-314-(3-di-n-butylaminopropoxy)benzoy1]-5-methylsulfonamidobenzofuran oxalate ~~comprises~~ ; and at least one amphiphilic lipid excipient with HLB value between 2 and 20 selected from the semi-solid substituted glycerides, the liquid substituted glycerides, the semi-solid substituted polyoxylglycerides, the liquid substituted polyoxylglycerides and mixtures thereof..

~~2. The composition as claimed in the preceding claim, characterized in that the 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran in the form of a pharmaceutically acceptable salt is selected from 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran hydrochloride, 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran fumarate and 2-n-butyl-314-(3-di-n-butylaminopropoxy)benzoy1]-5-methylsulfonamidobenzofuran oxalate.~~

~~3.~~2. The composition as claimed in either one of the preceding claims, ~~characterized in that~~wherein the active principle is selected from 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran in the form of base and -n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran hydrochloride.

~~4.~~3. The composition as claimed in any one of the preceding claims, ~~characterized in that~~wherein said composition further comprises at least one surfactant and/or at least one co-solvent.

~~5.~~4. The composition as claimed in any one of the preceding claims, ~~characterized in that~~wherein said amphiphilic lipid excipient with HLB value between 2 and 20 has a melting point below 50°C.

~~6. The composition as claimed in any one of the preceding claims, characterized in that said lipid excipient is selected from the semi-solid substituted glycerides, the liquid substituted glycerides, the semi-solid substituted polyoxylglycerides, the liquid substituted polyoxylglycerides and mixtures thereof.~~

~~7.~~5. The composition as claimed in any one of the preceding claims, ~~characterized in that~~wherein said lipid excipient is selected from the Gelucires marketed under the brand name Gelucire® 33/01, Gelucire® 39/01, Gelucire® 43/01, Geleol® and Peceol™, the glycerides marketed under the name Labrafac Lipophile® WL1349, the Gelucires marketed under the brand name Gelucire® 44/14 and Gelucire® 50/13, the polyoxylglycerides marketed under the brand name Labrafil®M1944CS, Labrafil®M2125CS, Labrafil®M2130CS and Labrasol®, the medium-chain mono- and diglycerides marketed under the name Capmul MCM®, propylene glycol monolaurate marketed under the name Lauroglycol® 90 and Capmul PG12®, the caprylocaproyl macrogol-8 glycerides marketed under the name Labrasol®, the propylene glycol caprylic acid monoester marketed under the name Capmul® PG-8 and mixtures thereof.

~~8.~~6. The composition as claimed in any one of the preceding claims, ~~characterized in that~~wherein said lipid excipient is selected from the lipid excipients having an HLB value between 5 and 18.

~~9.~~7. The composition as claimed in claim ~~8~~6, ~~characterized in that~~wherein said lipid excipient is selected from the lipid excipients sold under the trade name Capmul MCM®, Lauroglycol® 90, Capmul PG12®, Labrasol®, Gelucire® 44/14, Gelucire® 50/13 and Capmul® PG-8.

~~10.~~8. The composition as claimed in any one of the preceding claims, ~~characterized in that~~wherein it comprises 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran hydrochloride, as active principle and/or at least one semi-solid substituted polyoxylglyceride as lipid excipient.

~~11.~~9. The composition as claimed in one of the preceding claims, ~~characterized in that~~wherein it comprises:

- 1-60 wt% of at least one active principle;
- 40-99 wt% of at least one lipid excipient;
- 0-30 wt% of at least one compound selected from surfactants, co-solvents, diluents, disintegrants, lubricants, organic or inorganic bases and plasticizers,

the percentages being expressed by weight relative to the total weight of said composition.

~~12.~~10. The composition as claimed in one of the preceding claims, ~~characterized in that~~wherein it comprises:

- 1-60 wt% of at least one active principle;
- 40-99 wt% of at least one lipid excipient;
- 0-30 wt% of at least one surfactant, and
- 0-29 wt% of at least one co-solvent;

the percentages being expressed by weight relative to the total weight of said composition.

~~13.~~11. The composition as claimed in one of claims ~~11~~ 9 or ~~12~~10, ~~characterized in that~~wherein it comprises:

- 1-50wt% of at least one active principle, advantageously between 10 and 45%, even better between 20% and 40%;

and/or

- 45-80wt% of at least one lipid excipient, advantageously between 50% and 60%;

and/or

- 1-20 wt% of at least one surfactant, advantageously between 5% and 15%;

and/or

- 1-20 wt% of at least one co-solvent, advantageously between 2 and 15%.

~~14.~~12. The composition as claimed in one of claims ~~11~~ 9 to ~~13~~11, ~~characterized in that~~wherein the surfactant is hydrophilic and nonionic.

~~15.~~13. The composition as claimed in one of claims ~~11~~ 9 to ~~14~~12, ~~characterized in that~~wherein the surfactant is selected from:

- ethylene oxide/propylene oxide copolymers;
- polyethoxylated castor oils;
- ethoxylated polysorbates, and
- polyethylene hydroxystearates

~~16.~~14. The composition as claimed in any one of claims ~~11~~ 9 to ~~15~~13, ~~characterized in that~~wherein the surfactant is poloxamer 407.

~~17.~~15. The composition as claimed in any one of claims ~~11~~-9 to ~~16~~14, ~~characterized in that~~wherein the co-solvent is selected from the alcoholic organic solvents or the glycol derivatives.

~~18.~~16. A dosage form comprising a composition as claimed in any one of claims 1 to ~~17~~15.

~~19.~~17. The dosage form as claimed in claim ~~18~~16, ~~characterized in that~~wherein it is a capsule selected from hard capsules, soft shell capsules, enteric capsules and modified-release capsules.

~~20.~~18. The dosage form as claimed in either one of claims ~~18~~ 16 to ~~19~~17, characterized in that it is a hard capsule.

~~21.~~19. The dosage form as claimed in any one of claims ~~18~~ 16 to ~~20~~18, ~~characterized in that~~wherein it contains between 50 and 500 mg of active principle, advantageously between 200 and 400 mg of active principle.